文献速递眼底病与葡萄膜炎神经眼科

美国男性使用磷酸二酯酶5抑制剂与眼部不良事件风险

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

该队列研究嵌套病例对照分析利用2006年1月1日至2020年12月31日PharMetrics Plus数据库,纳入213 033名使用磷酸二酯酶5抑制剂(PDE5Is)的男性,评估浆液性视网膜脱离(SRD)、视网膜血管阻塞(RVO)和缺血性视神经病变(ION)风险。调整混杂后,PDE5Is规律使用者复合终点调整IRR为1.85(95%CI 1.41-2.42),SRD、RVO、ION的调整IRR分别为2.58(95%CI 1.55-4.30)、1.44(95%CI 0.98-2.12)和2.02(95%CI 1.14-3.58)。作者认为规律使用PDE5Is可能增加SRD、RVO和ION风险,使用者需警惕视觉障碍并告知医生。

要点

  • 规律使用PDE5Is者复合终点调整IRR为1.85(95%CI 1.41-2.42)。
  • SRD调整IRR为2.58,RVO为1.44(95%CI跨1),ION为2.02。
  • 作者认为规律使用者可能增加SRD、RVO和ION风险。

核心结论

  • 作者认为规律使用PDE5Is可能增加SRD、RVO和ION风险。
  • 规律使用PDE5Is者需警惕相关眼部不良事件,出现视觉障碍时应告知医生。

研究设计与样本

  • 队列研究嵌套病例对照分析,数据来自PharMetrics Plus数据库(IQVIA),时间范围为2006年1月1日至2020年12月31日。
  • 队列由213 033名接受PDE5Is(包括西地那非、他达拉非、伐地那非和阿伐那非)的男性组成。
  • 病例对照分析纳入1146例SRD(278例)、RVO(628例)和ION(240例)及4584名对照,两组平均(SD)年龄均为64.6(13.3)岁。
  • 每个病例按年龄和研究进入时间以密度采样匹配4名对照,排除队列前一年内诊断SRD、RVO或ION者。
  • 采用条件logistic回归计算调整发病率比(IRR)及95%CI,控制高血压、冠心病、吸烟和糖尿病(所有3个结局)以及睡眠呼吸暂停(ION结局)。

主要发现

  • SRD、RVO和ION患者更可能患有高血压、糖尿病、冠心病和睡眠呼吸暂停。
  • 任何3种结局复合终点的调整IRR为1.85(95%CI 1.41-2.42;发病率15.5例/10 000人年)。
  • SRD的调整IRR为2.58(95%CI 1.55-4.30;发病率3.8例/10 000人年)。
  • RVO的调整IRR为1.44(95%CI 0.98-2.12;发病率8.5例/10 000人年)。
  • ION的调整IRR为2.02(95%CI 1.14-3.58;发病率3.2例/10 000人年)。

临床怎么用

  • 原文未据此给出推荐,仅作者认为规律使用PDE5Is者需警惕眼部不良事件,出现视觉障碍时应告知医生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A number of case reports and small epidemiologic studies have quantified the risk of ocular adverse events associated with the use of phosphodiesterase type 5 inhibitors (PDE5Is). However, results have been conflicting, and epidemiologic data on the risk of serous retinal detachment (SRD) and retinal vascular occlusion (RVO) are not available. OBJECTIVE: To quantify the risk of SRD, RVO, and ischemic optic neuropathy (ION) associated with the use of PDE5Is. DESIGN, SETTING, AND PARTICIPANTS: This cohort study with a nested case-control analysis was performed using data obtained from the PharMetrics Plus database (IQVIA) from January 1, 2006, to December 31, 2020. Cohort members were followed up until the first diagnosis of SRD, RVO, or ION or termination of insurance coverage. For each case, 4 controls were matched by age and time of study entry using density-based sampling. Risk for regular users of PDE5Is was compared with that for nonusers, adjusting for potential confounding variables. Cases with diagnoses of SRD, RVO, and ION in the year before the cohort were excluded. MAIN OUTCOMES AND MEASURES: First diagnosis of SRD, RVO, or ION identified by International Classification of Diseases, Ninth Revision or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes. Adjusted incidence rate ratios (IRRs) with 95% CIs were calculated using conditional logistic regression, controlling for hypertension, coronary artery disease, smoking, and diabetes (for all 3 outcomes) as well as sleep apnea for the ION outcome. RESULTS: The cohort consisted of 213 033 men receiving PDE5Is, including sildenafil, tadalafil, vardenafil, and avanafil. The case-control analysis included a total of 1146 cases of SRD (278), RVO (628), and ION (240) and 4584 controls, and the mean (SD) age in both groups was 64.6 (13.3) years. Patients with SRD, RVO, and ION were more likely to have hypertension, diabetes, coronary artery disease, and sleep apnea. The adjusted IRR for the composite end points of any of the 3 outcomes was 1.85 (95% CI, 1.41-2.42; incidence, 15.5 cases per 10 000 person-years). The adjusted IRR for SRD, RVO, and ION as individual outcomes was 2.58 (95% CI, 1.55-4.30; incidence, 3.8 cases per 10 000 person-years), 1.44 (95% CI, 0.98-2.12; incidence, 8.5 cases per 10 000 person-years), and 2.02 (95% CI, 1.14-3.58; incidence, 3.2 cases per 10 000 person-years), respectively. CONCLUSIONS AND RELEVANCE: Findings of this cohort study suggest that regular users of PDE5Is might have an increased risk for SRD, RVO, and ION. Regular users of PDE5Is need to be cognizant of ocular adverse events associated with these drugs and alert their physicians if they experience any visual deficits.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Etminan M, Sodhi M, Mikelberg FS, et al. Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol. 2022. PMID: 35389459. doi:10.1001/jamaophthalmol.2022.0663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。